Carl-Åke Carlsson is a seasoned executive with a distinguished career in the pharmaceutical industry, recognized for his visionary leadership and strategic acumen. With an MBA from Heriot-Watt Business School and a Bachelor’s degree in Business Administration from Oslo Business School, he has spearheaded transformative initiatives at Xellia Pharmaceuticals and Alpharma. Notably, at Xellia, he led the launch of the first-ever Ready-To-Use, room temperature-stable Vancomycin premix in the U.S. institutional market. In november 2024, he became CEO of DelSiTech in Turku

Beyond his executive roles, Carl-Åke brings extensive board experience, currently serving as Chairman and Strategic Advisor for several technology-driven international companies. His career is defined by a proven ability to craft and execute long-term strategies, foster high-performing teams, and drive innovation in the pharmaceutical and healthcare sectors.

In the InFlames side event on 21.5., Carl-Åke will talk about leadership and transformation in pharma and biotech companies, significant change of strategy and business model and how to grow out of research and sophisticated lab operations into a fully-fledged commercial entity.

The listeners will learn about honesty in recognizing the known unknowns and trying to anticipate the unknow unknowns, what is the importance of having people with the right background, experience and skillset and recognizing that this will change over time. They will also learn how to build teams under ambiguity.